0001209191-22-038659.txt : 20220622 0001209191-22-038659.hdr.sgml : 20220622 20220622160403 ACCESSION NUMBER: 0001209191-22-038659 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20220619 FILED AS OF DATE: 20220622 DATE AS OF CHANGE: 20220622 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hayden Tanya CENTRAL INDEX KEY: 0001934603 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33004 FILM NUMBER: 221032040 MAIL ADDRESS: STREET 1: 300 WASHINGTON STREET STREET 2: ONE GATEWAY CENTER, SUITE 351 CITY: NEWTON STATE: MA ZIP: 02458 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Acer Therapeutics Inc. CENTRAL INDEX KEY: 0001069308 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 320426967 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE GATEWAY CENTER (300 WASHINGTON ST.) STREET 2: SUITE 356 CITY: NEWTON STATE: MA ZIP: 02458 BUSINESS PHONE: (844) 902-6100 MAIL ADDRESS: STREET 1: ONE GATEWAY CENTER (300 WASHINGTON ST.) STREET 2: SUITE 356 CITY: NEWTON STATE: MA ZIP: 02458 FORMER COMPANY: FORMER CONFORMED NAME: Opexa Therapeutics, Inc. DATE OF NAME CHANGE: 20060616 FORMER COMPANY: FORMER CONFORMED NAME: PharmaFrontiers Corp. DATE OF NAME CHANGE: 20051011 FORMER COMPANY: FORMER CONFORMED NAME: PHARMAFRONTIERS CORP DATE OF NAME CHANGE: 20040816 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2022-06-19 0 0001069308 Acer Therapeutics Inc. ACER 0001934603 Hayden Tanya 300 WASHINGTON STREET ONE GATEWAY CENTER, SUITE 356 NEWTON MA 02458 0 1 0 0 Chief Operating Officer Employee Stock Option (right to buy) 2.96 2031-06-01 Common Stock 30000 D Employee Stock Option (right to buy) 2.21 2032-01-14 Common Stock 12500 D The option vests and becomes exercisable over four years as follows: 25% of the shares vest on the one-year anniversary of the grant date, and the remaining 75% of the shares vest quarterly over the remaining three years. The option was granted on June 1, 2021. The option vests and becomes exercisable over four years as follows: 25% of the shares vest on the one-year anniversary of the grant date, and the remaining 75% of the shares vest quarterly over the remaining three years. The option was granted on January 14, 2022. Exhibit List: Exhibit 24 - Confirming Statement /s/ Harry S. Palmin, Attorney-in-Fact 2022-06-22 EX-24 2 attachment1.htm EX-24 DOCUMENT

                                                                     Exhibit 24

CONFIRMING STATEMENT

       This Statement confirms that the undersigned has authorized and
designated each of Harry S. Palmin, Jason Kneeland and Donald R. Joseph (each
an "attorney-in-fact"), each acting singly, to execute and file or cause to be
filed on the undersigned's behalf a Form ID and all Forms 3, 4, and 5 (including
any amendments thereto) that the undersigned may be required to file with the
U.S. Securities and Exchange Commission as a result of the undersigned's
ownership of or transactions in securities of Acer Therapeutics Inc. The
undersigned hereby grants to each attorney-in-fact full power and authority to
do and perform any and every act and thing whatsoever requisite, necessary or
proper to be done in the exercise of any of the rights and powers herein
granted, as fully to all intents and purposes as the undersigned might or could
do personally present, with full power of substitution, resubstitution or
revocation, hereby ratifying and confirming all that such attorney-in-fact, or
such attorney's-in-fact substitute or substitutes, shall lawfully do or cause to
be done by virtue of this power of attorney and the rights and powers herein
granted. The authority of each attorney-in-fact under this Statement shall
continue until the undersigned is no longer required to file Forms 3, 4, and 5
with regard to the undersigned's ownership of or transactions in securities of
Acer Therapeutics Inc. unless earlier revoked in writing. The undersigned
acknowledges that none of the attorneys-in-fact are assuming any of the
undersigned's responsibilities to comply with Section 16 of the Securities
Exchange Act of 1934.

       This Statement revokes the authority of any person named in any prior
confirming statement relating to the undersigned's filing obligations with
respect to securities of Acer Therapeutics Inc. who is not named herein, and
this Statement replaces and supersedes any such prior confirming statement.



Signed:	/s/ Tanya Hayden
Print Name: Tanya Hayden
Dated: 	6/22/22